Crosstalk Between Innate and T Cell Adaptive Immunity With(in) the Muscle

Archive ouverte

Bonomo, Adriana, C. | Pinto-Mariz, Fernanda | Riederer, Ingo | Benjamim, Claudia, F. | Butler-Browne, Gillian | Mouly, Vincent | Savino, Wilson

Edité par CCSD ; Frontiers -

International audience. Growing evidence demonstrates a continuous interaction between the immune system and the skeletal muscle in inflammatory diseases of different pathogenetic origins, in dystrophic conditions such as Duchenne Muscular Dystrophy as well as during normal muscle regeneration. Although one component of the innate immunity, the macrophage, has been extensively studied both in disease conditions and during cell or gene therapy strategies aiming at restoring muscular functions, much less is known about dendritic cells and their primary immunological targets, the T lymphocytes. This review will focus on the dendritic cells and T lymphocytes (including effector and regulatory T-cells), emphasizing the potential cross talk between these cell types and their influence on the structure and function of skeletal muscle.

Suggestions

Du même auteur

Activated dendritic cells modulate proliferation and differentiation of human myoblasts

Archive ouverte | Ladislau, Leandro | CCSD

International audience. Idiopathic Inflammatory Myopathies (IIMs) are a heterogeneous group of autoimmune diseases affecting skeletal muscle tissue homeostasis. They are characterized by muscle weakness and inflamma...

CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy

Archive ouverte | Pinto-Mariz, Fernanda | CCSD

International audience. Background: Duchenne muscular dystrophy (DMD) is caused by mutations in the dystrophin gene. The immune inflammatory response also contributes to disease progression in DMD patients. In a pre...

Predictive markers of clinical outcome in the GRMD dog model of Duchenne muscular dystrophy

Archive ouverte | Barthélémy, Inès | CCSD

International audience. In the translational process of developing innovative therapies for DMD (Duchenne muscular dystrophy), the last preclinical validation step is often carried out in the most relevant animal mo...

Chargement des enrichissements...